References
- Karnak I, Senocak ME, Ciftci AO, Cağlar M, Bingöl-Koloğlu M, Tanyel FC, Büyükpamukçu N. Inflammatory myofibroblastic tumor in children: diagnosis and treatment. J Pediatr Surg. 2001 Jun;36(6):908–12. doi:https://doi.org/10.1053/jpsu.2001.23970.
- Saab ST, Hornick JL, Fletcher CD, Olson SJ, Coffin CM. IgG4 plasma cells in inflammatory myofibroblastic tumor: inflammatory marker or pathogenic link? Mod Pathol. 2011 Feb;24(4):606–12. doi:https://doi.org/10.1038/modpathol.2010.226.
- Chang JC, Zhang L, Drilon AE, Chi P, Alaggio R, Borsu L, Benayed R, Travis WD, Ladanyi M, Antonescu CR, et al. Expanding the molecular characterization of thoracic inflammatory myofibroblastic tumors beyond ALK gene rearrangements. J Thorac Oncol. 2019 May;14(5):825–34. doi:https://doi.org/10.1016/j.jtho.2018.12.003.
- Antonescu CR, Suurmeijer AJH, Zhang L, Sung YS, Jungbluth AA, Travis WD, Al-Ahmadie H, Fletcher CDM, Alaggio R. Molecular characterization of inflammatory myofibroblastic tumors with frequent ALK and ROS1 gene fusions and rare novel RET rearrangement. Am J Surg Pathol. 2015 Jul;39(7):957–67. doi:https://doi.org/10.1097/PAS.0000000000000404.
- Mehta B, Mascarenhas L, Zhou S, Wang L, Venkatramani R. Inflammatory myofibroblastic tumors in childhood. Pediatr Hematol Oncol. 2013 Oct;30(7):640–5. doi:https://doi.org/10.3109/08880018.2013.816810.
- Neuhauser TS, Derringer GA, Thompson LD, et al. Splenic inflammatory myofibroblastic tumor (inflammatory pseudotumor): a clinicopathologic and immunophenotypic study of 12 cases. Arch Pathol Lab Med. 2001 Mar;125:379–85.
- Gong S, Auer I, Duggal R, Pittaluga S, Raffeld M, Jaffe ES. Epstein-Barr virus-associated inflammatory pseudotumor presenting as a colonic mass. Hum Pathol. 2015 Dec;46(12):1956–61. doi:https://doi.org/10.1016/j.humpath.2015.08.011.
- Palomeque Jiménez A, Reyes Moreno M, Calzado Baeza S, Ranea Jimena SA, Robayo Soto PS. Detection of Epstein–Barr virus in an inflammatory myofibroblastic tumor of the spleen (inflammatory pseudotumor. Cir Esp. 2015 Jan;93(6):e41–e43. doi:https://doi.org/10.1016/j.cireng.2015.05.004.
- Butrynski JE, D’Adamo DR, Hornick JL, Dal Cin P, Antonescu CR, Jhanwar SC, Ladanyi M, Capelletti M, Rodig SJ, Ramaiya N, et al. Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor. N Engl J Med. 2010 Oct;363(18):1727–33. doi:https://doi.org/10.1056/NEJMoa1007056.
- Yamamoto H, Yoshida A, Taguchi K, Kohashi K, Hatanaka Y, Yamashita A, Mori D, Oda Y. ALK, ROS1 and NTRK3 gene rearrangements in inflammatory myofibroblastic tumours. Histopathology. 2016 Jul;69(1):72–83. doi:https://doi.org/10.1111/his.12910.
- Coffin CM, Patel A, Perkins S, Elenitoba-Johnson KS, Perlman E, Griffin CA. ALK1 and p80 Expression and chromosomal rearrangements involving 2p23 in inflammatory myofibroblastic tumor. Mod Pathol. 2001;14(6):569–76. doi:https://doi.org/10.1038/modpathol.3880352.
- Lovly CM, Gupta A, Lipson D, Otto G, Brennan T, Chung CT, Borinstein SC, Ross JS, Stephens PJ, Miller VA, et al. Inflammatory myofibroblastic tumors harbor multiple potentially actionable kinase fusions. Cancer Discov. 2014 Aug;4(8):889–95. doi:https://doi.org/10.1158/2159-8290.CD-14-0377.
- Sholl LM, Sun H, Butaney M, Zhang C, Lee C, Jänne PA, Rodig SJ. ROS1 immunohistochemistry for detection of ROS1-rearranged lung adenocarcinomas. Am J Surg Pathol. 2013 Sep;37(9):1441–9. doi:https://doi.org/10.1097/PAS.0b013e3182960fa7.
- Hornick JL, Sholl LM, Dal Cin P, Childress MA, Lovly CM. Expression of ROS1 predicts ROS1 gene rearrangement in inflammatory myofibroblastic tumors. Mod Pathol. 2015 May;28(5):732–9. doi:https://doi.org/10.1038/modpathol.2014.165.
- Schöffski P, Sufliarsky J, Gelderblom H, Blay JY, Strauss SJ, Stacchiotti S, Rutkowski P, Lindner LH, Leahy MG, Italiano A, et al. Crizotinib in patients with advanced, inoperable inflammatory myofibroblastic tumours with and without anaplastic lymphoma kinase gene alterations (European Organisation for Research and Treatment of Cancer 90101 CREATE): a multicentre, single-drug, prosp. Lancet Respir Med. 2018 Jun;6(6):431–41. doi:https://doi.org/10.1016/S2213-2600(18)30116-4.
- Ogata M, Hatachi Y, Ogata T, Satake H, Imai Y, Yasui H. Effectiveness of crizotinib for inflammatory myofibroblastic tumor with ALK mutation. Intern Med. 2019 Apr;58(7):1029–32. doi:https://doi.org/10.2169/internalmedicine.1640-18.